UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity

Journal of Chemotherapy

Volumn 20, Issue 2, 2008, Pages 158-165

  Biason, P ^a   Masier, S ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

APC: 7 ethyl 10 4 N (5 amino pentanoic acid) 1 piperidino carbonyloxycamptothecin; CRC: Colorectal cancer; hCE: Human carboxylesterases; NPC: 7 ethyl 10 4 (1 piperidino) 1 amino carbonyloxycamptothecin; SN38: 7 ethyl 10 hydroxycamptothecin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CAPECITABINE; CARBOXYLESTERASE; DOCETAXEL; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE;

AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DNA POLYMORPHISM; DRUG DETOXIFICATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ETHNIC DIFFERENCE; ETHNICITY; GENE CLUSTER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NEUTROPENIA; PROTEIN EXPRESSION; REVIEW; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; CHEMICALLY INDUCED DISORDER; GENETIC POLYMORPHISM; GENETICS; HAPLOTYPE; METASTASIS; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; GENE FREQUENCY; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPENIA; POLYMORPHISM, GENETIC;

EID: 44849107763     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.2.158     Document Type: Review

References (43)

1. Cersosimo RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 1998; 32(12):1324-1333.
2. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54 (14):3723-3725.
3. Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M et al. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Nippon Yakurigaku Zasshi 1995; 105 (6):447-460.
4. Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents 2003; 3 (3):225-237.
5. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60 (24):6921-6926.
6. Human UGT Allele nomenclature. http://som.flinders.edu.au/FUSA/ClinPharm/ UGT/. Last accessed May 04, 2007.
7. Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther 2006; 10 (3):175-185.
8. Mercke OJ, Andrade J, Holmberg K, Hoglund P, Malmqvist U, Odeberg J. UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol 2006; 62 (10):829-837.
9. Rauchschwalbe SK, Zuhlsdorf MT, Schuhly U, Kuhlmann J. Predicting the risk of sporadic elevated bilirubin levels and diagnosing Gilbert's syndrome by genotyping UGT1A1*28 promoter polymorphism. Int J Clin Pharmacol Ther 2002; 40 (6):233-240.
10. Sampietro M, Lupica L, Perrero L. Romano R, Molteni V, Fiorelli G. TATA-box mutant in the promoter of the uridine diphosphate glucuronosyltransferase gene in Italian patients with Gilbert's syndrome. Ital J Gastroenterol Hepatol 1998; 30 (2):194-198.
11. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyl-transferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999; 9 (5):591-599.
12. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75 (6):501-515.
13. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9 (8):845-847.
14. Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y. Genetic polymorphisms of the UDP-glucuronosyl-transferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 2002; 93 (5):591-597.
15. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22 (8): 1382-1388
16. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y. Polymorphism of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002M; 24 (1):111-116.
17. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91 (4):678-682.
18. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10 (15):5151-5159.
19. Revised Irinotecan label. American Food and Drug Administration. http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005- 4180b_05_05_Irinotecan%20label%207-21-05%20FDA.pdf Last accessed May 04, 2007.
20. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 2006; 16 (12):847-854.
21. Third Wave Technologies: Invader® UGT1A1 Assay package insert (2005). American Food and Drug Administration www.ons.org/fda/documents/FDA93005insert. pdf Last accessed May 04, 2007.
22. Van Bebber SL, Keegan HLPKAIAM. Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study. Personalized Medicine 2006; 3 (4):415-419.
23. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11 (3):1226-1236.
24. Font A, Sanchez JM, Taron M, Martinez-Balibrea E. Sanchez JJ, Manzano JL et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyl-transferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003; 21 (4):435-443.
25. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A. D'Andrea M et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24 (19):3061-3068.
26. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106 (5):1007-1016.
27. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24 (15):2237-2244.
28. Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K. Imaizumi K et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15 (1):35-41.
29. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292 (2):492-497.
30. Tang KS, Chiu HF, Chen HH, Eng HL, Tsai CJ, Teng HC et al. Link between colorectal cancer and polymorphisms in the uridine- diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J Gastroenterol 2005; 11 (21):3250-3254.
31. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003; 31 (1):108-113.
32. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97(11):1255-1259.
33. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12 (9):725-733.
34. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005; 15 (5):295-301.
35. Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J. Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 2006; 27 (7):717-730.
36. Innocenti F, Ratain MJ. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther 2004; 75 (6):495-500.
37. Goetz MP, Reid JM, Safgren SL, Mandrekar SJ, Erlichman C,. Adjei AA et al. UGT1A1*28 genotype determines the maximum tolerated dose (MTD) and pharmacokinetics (PK) of irinotecan-based chemotherapy: A phase I dose-escalation trial. ASCO Gastrointestinal Cancers Symposium 2007, abs 235.
38. Aono S, Yamada Y, Keino H, Hanada N, Nakagawa T, Sasaoka Y et al. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 1993; 197 (3):1239-1244.
39. Krishnaswamy S, Hao Q, Al Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 2005; 313 (3):1340-1346.
40. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006; 6 (1):63-75.
41. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyl-transferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10 (7):629-644.
42. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14 (5):329-332.
43. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2 (1):43-47.